Skip to content
Evigrade
MajorAntiepileptics. Carboxamide derivatives×HIV protease inhibitor / pharmacokinetic booster

Updated · Methodology

Mechanism

Ritonavir strongly inhibits CYP3A4 (ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). In the liver, this enzyme converts carbamazepine into its active metabolite, carbamazepine-10,11-epoxide. With ritonavir, whether as a low-dose booster or at the full antiretroviral dose, carbamazepine levels are therefore expected to rise (ritonavir SmPC, EMA; carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The effect also runs the other way. Carbamazepine is a strong CYP3A4 inducer and can lower the levels of human immunodeficiency virus (HIV) protease inhibitors, including ritonavir. Their effect may weaken or be lost completely (carbamazepine SmPC, AEMPS). The documents give no figures for ritonavir itself. But with nirmatrelvir/ritonavir, the combination used for COVID-19, carbamazepine reduced the nirmatrelvir area under the curve (AUC) by 55% and its peak concentration by 43% (nirmatrelvir/ritonavir SmPC, EMA).

Symptoms

High carbamazepine levels can cause dizziness, drowsiness, ataxia and double vision (carbamazepine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Lower levels of the antiviral drugs cause no symptoms by themselves, but treatment may lose its effect and the virus may become resistant (ritonavir label, US Food and Drug Administration, FDA; nirmatrelvir/ritonavir SmPC, European Medicines Agency, EMA). Stopping carbamazepine abruptly can trigger seizures (carbamazepine SmPC, AEMPS).

Management

The approach depends on the product in which the person takes ritonavir. Carbamazepine is contraindicated with nirmatrelvir/ritonavir, the combination used to treat COVID-19, because of the risk of losing the antiviral effect and of viral resistance (nirmatrelvir/ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). Nirmatrelvir/ritonavir also cannot be started immediately after carbamazepine is stopped, because the effect of a recently stopped CYP3A inducer wears off with a delay (nirmatrelvir/ritonavir SmPC, EMA). To time the start, the SmPC suggests considering a joint decision by physicians and clinical pharmacology specialists, bearing in mind that treatment needs to begin within 5 days of symptom onset (EMA). Do not stop carbamazepine abruptly, as seizures may follow. Withdraw it gradually over 6 months (carbamazepine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The ritonavir documents themselves do not prohibit the combination. Carefully monitor the therapeutic and adverse effects of carbamazepine (ritonavir SmPC, EMA). The carbamazepine dose may need to be reduced, and monitoring carbamazepine blood levels is recommended if the test is available (ritonavir FDA label). With human immunodeficiency virus (HIV) protease inhibitors such as ritonavir, the carbamazepine documents say to adjust the carbamazepine dose and/or monitor its levels. They also say to adjust protease inhibitor doses to clinical needs (carbamazepine SmPC, AEMPS, and FDA label). When low-dose ritonavir boosts another HIV protease inhibitor, check the contraindications in that drug's documents (ritonavir SmPC, EMA, and FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Carbamazepine

Other interactions with Ritonavir